{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:16:10Z","timestamp":1780528570362,"version":"3.54.1"},"reference-count":15,"publisher":"The Jutendo Medical Journal","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Juntendo Medical Journal"],"published-print":{"date-parts":[[2024]]},"DOI":"10.14789\/jmj.jmj24-0010-p","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T22:12:36Z","timestamp":1713391956000},"page":"125-128","source":"Crossref","is-referenced-by-count":6,"title":["Designing Future Clinical Trials for Sepsis-associated Disseminated          Intravascular Coagulation"],"prefix":"10.14789","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-2674","authenticated-orcid":false,"given":"CHERYL L.","family":"MAIER","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of              Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-4088","authenticated-orcid":false,"given":"TOSHIAKI","family":"IBA","sequence":"additional","affiliation":[{"name":"Department of Emergency and Disaster Medicine, Juntendo University Graduate              School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5768","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"[1] Iba              T, Nisio              MD, Levy              JH, Kitamura              N, Thachil              J: New criteria for          sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective          analysis of a nationwide survey. BMJ Open, 2017; 7:          e017046.","DOI":"10.1136\/bmjopen-2017-017046"},{"key":"2","doi-asserted-by":"crossref","unstructured":"[2] Thachil              J, Iba              T: Designing the diagnostic          criteria for disseminated intravascular coagulation (DIC). Juntendo Medical Journal, 2023;          69: 1-3.","DOI":"10.14789\/jmj.JMJ23-0038-P"},{"key":"3","doi-asserted-by":"crossref","unstructured":"[3] Umemura              Y, Yamakawa              K: Optimal patient selection          for anticoagulant therapy in sepsis: an evidence-based proposal from Japan. J Thromb          Haemost, 2018; 16: 462-464.","DOI":"10.1111\/jth.13946"},{"key":"4","doi-asserted-by":"crossref","unstructured":"[4] Yamakawa              K, Gando              S, Ogura              H, et al:          Identifying Sepsis Populations Benefitting from Anticoagulant Therapy: A Prospective          Cohort Study Incorporating a Restricted Cubic Spline Regression Model. Thromb Haemost,          2019; 119: 1740-1751.","DOI":"10.1055\/s-0039-1693740"},{"key":"5","doi-asserted-by":"crossref","unstructured":"[5] Iba              T, Maier              SL, Tanigawa              T, Levy              JH: Risk stratification          utilizing Sequential Organ Failure Assessment (SOFA) score, antithrombin activity, and          demographic data in sepsis-associated disseminated intravascular coagulation (DIC). Sci          Rep, 2023; 13: 22502.","DOI":"10.1038\/s41598-023-49855-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"[6] Tagami              T, Matsui              H, Horiguchi              H, Fushimi              K, Yasunaga              H: Antithrombin and mortality          in severe pneumonia patients with sepsis-associated disseminated intravascular          coagulation: an observational nationwide study. J Thromb Haemost, 2014; 12:          1470-1479.","DOI":"10.1111\/jth.12643"},{"key":"7","doi-asserted-by":"crossref","unstructured":"[7] Warren              BL, Eid              A, Singer              P, et al: Caring          for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized          controlled trial. JAMA, 2001; 286: 1869-1878.","DOI":"10.1001\/jama.286.15.1869"},{"key":"8","doi-asserted-by":"crossref","unstructured":"[8] Saito              H, Maruyama              I, Shimazaki              S, et al:          Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated          intravascular coagulation: results of a phase III, randomized, double-blind clinical          trial. J Thromb Haemost, 2007; 5: 31-41.","DOI":"10.1111\/j.1538-7836.2006.02267.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"[9] Vincent              JL, Francois              B,                Zabolotskikh              I, et al: Effect          of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With          Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA, 2019; 321:          1993-2002.","DOI":"10.1001\/jama.2019.5792"},{"key":"10","doi-asserted-by":"crossref","unstructured":"[10] Iba              T, Saitoh              D, Wada              H, Asakura              H. Efficacy and bleeding risk          of antithrombin supplementation in septic disseminated intravascular coagulation: a          secondary survey. Crit Care, 2014; 18: 497.","DOI":"10.1186\/s13054-014-0497-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"[11] Akahoshi              T, Kaku              N, Shono              Y, et al:          Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients          with Sepsis-Induced Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost, 2022;          28: 10760296221135790.","DOI":"10.1177\/10760296221135790"},{"key":"12","unstructured":"[12] Fowler              AA              3rd, Truwit              JD, Hite              RD, et al: Effect          of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury          in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized          Clinical Trial. JAMA, 2019; 322: 1261-1270."},{"key":"13","doi-asserted-by":"crossref","unstructured":"[13] Bakal              JA,                Westerhout              CM, Armstrong              PW: Impact of weighted          composite compared to traditional composite endpoints for the design of randomized          controlled trials. Stat Methods Med Res, 2015; 24: 980-988.","DOI":"10.1177\/0962280211436004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"[14] McCoy              CE: Understanding the Use of          Composite Endpoints in Clinical Trials. West J Emerg Med, 2018; 19:          631-634.","DOI":"10.5811\/westjem.2018.4.38383"},{"key":"15","doi-asserted-by":"crossref","unstructured":"[15] Cools              F, Virdone              S, Sawhney              J, et al:          Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated,          at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised,          controlled, phase 3b trial. Lancet Haematol, 2022; 9: e594-e604.","DOI":"10.1016\/S2352-3026(22)00173-9"}],"container-title":["Juntendo Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmj\/70\/2\/70_JMJ24-0010-P\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T04:12:40Z","timestamp":1714795960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmj\/70\/2\/70_JMJ24-0010-P\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.14789\/jmj.jmj24-0010-p","relation":{},"ISSN":["2187-9737","2188-2126"],"issn-type":[{"value":"2187-9737","type":"print"},{"value":"2188-2126","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"JMJ24-0010-P"}}